Ticker > Company >

Sun Pharma Inds. share price

Sun Pharmaceutical Industries Ltd.

NSE: SUNPHARMA BSE: 524715 SECTOR: Pharmaceuticals & Drugs  448k   2k   543

1688.70
+1.70 (0.10%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 1699.5

Today's Low

₹ 1652.35

52 Week High

₹ 1960.2

52 Week Low

₹ 1461.4

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

405175.7 Cr.

Enterprise Value

415883.92 Cr.

No. of Shares

239.93 Cr.

P/E

94.61

P/B

16.65

Face Value

₹ 1

Div. Yield

0.95 %

Book Value (TTM)

₹  101.44

CASH

338.39 Cr.

DEBT

11046.61 Cr.

Promoter Holding

54.48 %

EPS (TTM)

₹  17.85

Sales Growth

-2.58%

ROE

12.05 %

ROCE

12.81%

Profit Growth

69.05 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Sun Pharmaceutical Industries Ltd.

Molxvir Gloeye Prazopress Pantocid Predmet Garlic Pearls REVITAL VOLINI PEPFIZ Diamox Deslor Cepodem Colvac Livcare Montek Mox CV Nexito Abzorb Faringosept

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-2.58%
3 Year12.83%
5 Year14.5%

Profit Growth

1 Year69.05%
3 Year50.26%
5 Year28.47%

ROE%

1 Year12.05%
3 Year6.22%
5 Year7.11%

ROCE %

1 Year12.81%
3 Year7.43%
5 Year7.59%

Debt/Equity

0.4662

Price to Cash Flow

-1385.6

Interest Cover Ratio

5.3996

CFO/PAT (5 Yr. Avg.)

1.02798134655305

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 54.48 0.88
Dec 2024 54.48 0.69
Sep 2024 54.48 0.79
Jun 2024 54.48 1.07
Mar 2024 54.48 2.05
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 50.2647359659939% for the Past 3 years.
  • The Company has been maintaining an effective average operating margins of 21.7481220234021% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 23.2817 days.
  • Company has a healthy liquidity position with current ratio of 3.3553.
  • The company has a high promoter holding of 54.48%.

 Limitations

  • The company has shown a poor revenue growth of 12.8279198272913% for the Past 3 years.
  • Company has a poor ROE of 6.21886280846473% over the past 3 years.
  • Promoter pledging has increased from 0.686233877219073% to 0.88% in 1 quarter.
  • Company has negative cash flow from operations of -292.42.
  • The company is trading at a high PE of 94.61.
  • The company is trading at a high EV/EBITDA of 57.975.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 5639.14 4498.07 5127.71 6191.81 7185.74
Total Expenditure 3745.61 3737 3917.42 4488.34 4428.09
Operating Profit 1893.53 761.07 1210.29 1703.47 2757.65
Other Income 118.88 82.74 214.63 68.39 363.81
Interest 217.59 216.08 243.75 215.96 217.42
Depreciation 393.04 369.81 285.53 290.97 291.96
Exceptional Items 0 0 0 0 0
Profit Before Tax 1401.78 257.92 895.64 1264.93 2612.08
Tax 534.18 20.1 32.35 83.88 611.62
Profit After Tax 867.6 237.82 863.29 1181.05 2000.46
Adjusted EPS (Rs) 3.62 0.99 3.6 4.92 8.34

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 12531.93 14116.05 15585.98 20812.14 20275.17
Total Expenditure 9820.28 11859.04 12917.42 14389.54 14775.28
Operating Profit 2711.65 2257.01 2668.56 6422.6 5499.89
Other Income 1510.92 192.07 1196.88 329.29 553.48
Interest 408.01 267.52 388.1 472.18 784.08
Depreciation 561.56 1236.43 1349.95 1600.87 1600.62
Exceptional Items 0 -89.56 -1820.53 -2937.79 -219.02
Profit Before Tax 3253 855.57 306.86 1741.05 3449.65
Tax 41.86 13.17 406.85 50.33 591.47
Net Profit 3211.14 842.4 -99.99 1690.72 2858.18
Adjusted EPS (Rs.) 13.38 3.51 -0.42 7.05 11.91

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 239.93 239.93 239.93 239.93 239.93
Total Reserves 24156.29 26698.54 24348.02 23508.43 23454.47
Borrowings 1256.69 5300.02 4865.64 7586.73 11036.01
Other N/C liabilities 1890.56 1928.04 1498.21 1622.92 2809.79
Current liabilities 11203.74 9951.33 10105.83 8365.44 4444.51
Total Liabilities 38747.21 44117.86 41057.63 41324.07 41985.34
Assets
Net Block 5228.74 9668.79 9712.78 8711.67 7736.74
Capital WIP 384.35 459.2 358.94 328.87 388.24
Intangible WIP 212.26 631.18 469.7 524.04 377.87
Investments 16966.65 15506.2 15355.83 12412.98 12429.97
Loans & Advances 4013.14 5120.85 5451.94 2866.3 6077.91
Other N/C Assets 0.95 1.56 4.69 36.46 62.07
Current Assets 11941.12 12730.08 9703.75 16443.75 14912.54
Total Assets 38747.21 44117.86 41057.63 41324.07 41985.34
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 3253 855.57 306.86 1741.05 3449.65
Adjustment -217.09 1717.87 1266.29 4823.4 1768.91
Changes in Assets & Liabilities -1393 -2752.28 3903.67 -5625.38 -5169.11
Tax Paid -337.06 -237.67 2159.54 -431.99 -341.87
Operating Cash Flow 1305.85 -416.51 7636.36 507.08 -292.42
Investing Cash Flow 1483.04 1452.47 -2697.04 -685.64 -265.35
Financing Cash Flow -2871.15 -999.73 -4870.85 169.31 473.95
Net Cash Flow -82.26 36.23 68.47 -9.25 -83.82

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 54.48 54.48 54.48 54.48 54.48
aalok dilip shanghvi 0.12 0.12 0.12 0.12 0.12
aditya medisales limited 1.67 1.67 1.67 1.67 1.67
dilip.s.shanghvi - - 9.60 9.60 9.60
raksha sudhir valia - - - - 1.20
shanghvi family & friends... 0.05 0.05 0.05 0.05 0.05
shanghvi finance private ... 40.30 40.30 40.30 40.30 40.30
sudhir v. valia 0.60 0.60 0.60 0.60 0.60
unimed investments limite... 0.43 0.43 0.43 0.43 0.43
vibha dilip shanghvi 0.37 0.37 0.37 0.37 0.37
vidhi dilip shanghvi 0.12 0.12 0.12 0.12 0.12
raksha s.valia 1.20 1.20 1.20 1.20 -
dilip s. shanghvi - 9.60 - - -
dilip. s. shanghvi 9.60 - - - -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 45.52 45.52 45.52 45.52 45.52
hdfc trustee company ltd.... - 1.01 1.03 1.12 1.13
icici prudential value di... 3.15 4.06 3.40 3.26 3.35
investor education and pr... 0.12 - 0.11 - 0.12
lakshdeep investments & f... - 1.02 - 1.02 1.02
life insurance corporatio... 2.92 3.10 3.14 2.93 3.04
llp 0.27 0.26 0.26 0.26 0.26
nps trust- a/c hdfc pensi... - - - 1.18 1.20
sbi nifty 50 etf 2.27 2.10 2.18 2.19 2.04
government pension fund g... 1.04 - 1.01 1.01 -
investor education and pr... - 0.11 - 0.12 -
lakshdeep investments & f... - - 1.02 - -
nps trust- a/c hdfc pensi... - 1.19 1.17 - -

Annual Reports

Title Action
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY ACTION
Credit CRISIL
Credit CRISIL
TYPE AGENCY ACTION
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research IDBI Capital
Research BOB Capital Market
Research BOB Capital Market
Research Edelweiss
Research HDFC Securities
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research Geojit BNP Paribas
Research Dolat Capital
Research BOB Capital Markets Ltd.
Research ICICI Securities Limited
Research SMC online
Research Nirmal Bang Institutional

Concalls & Presentations

TYPE QUARTER ACTION
Concall Q4FY24
Concall Q4FY23
Concall Q4FY22
Concall Q4FY21
Concall Q4FY19
Concall Q3FY24
Concall Q3FY22
Concall Q3FY21
Concall Q2FY24
Concall Q2FY22
Concall Q2FY21
Concall Q1FY25
Concall Q1FY24
Concall Q1FY22
Concall Q1FY21
TYPE QUARTER ACTION
Presentation Q3FY25
Presentation Q3FY24
Presentation Q3FY23
Presentation Q3FY22
Presentation Q3FY21
Presentation Q3FY20
Presentation Q2FY25
Presentation Q2FY24
Presentation Q2FY21
Presentation Q1FY25
Presentation Q1FY24
Presentation Q1FY24
Presentation Q1FY23
Presentation Q1FY21
Presentation Q1FY20
Presentation FY2024

Company News

Sun Pharma Inds. Stock Price Analysis and Quick Research Report. Is Sun Pharma Inds. an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Sun Pharma Inds. and its performance over the period of time. Sun Pharma Inds. stock price today is Rs 1687.8.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Sun Pharma Inds. cash from the operating activity was Rs -292.42 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Sun Pharma Inds. has a Debt to Equity ratio of 0.4662 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Sun Pharma Inds. , the EPS growth was 69.0522 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Sun Pharma Inds. has OPM of 27.1262337134535 % which is a good sign for profitability.
     
  • ROE: Sun Pharma Inds. have a average ROE of 12.049 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Sun Pharma Inds. is Rs 1687.8. One can use valuation calculators of ticker to know if Sun Pharma Inds. share price is undervalued or overvalued.
Last Updated on:
Brief about Sun Pharma Inds.
X